High Frequencies of Exposure to the Novel Human Parvovirus PARV4 in Hemophiliacs and Injection Drug Users, as Detected by a Serological Assay for PARV4 Antibodies

Abstract

The present study provides convincing evidence that PARV4 is primarily transmitted parenterally. Evidence for widespread infection of hemophiliacs treated with nonvirally inactivated clotting factor creates fresh safety concerns for plasma-derived blood products, particularly because parvoviruses are relatively resistant to virus inactivation.